Meng Qian is willing to invest in artificial intelligence, and he can predict part of the future technology trends in his mind - artificial intelligence will be explosive and wide-ranging, it is the future. And now that there is the best team and the most generous investors, why not join?

On his own, it is absolutely impossible to solve the discipline of artificial intelligence. Take a look at the AI lab, where investors have invested tens of billions of dollars, and then look at the top experts in various fields, some of whom have been in large companies and research institutes, and some have made significant achievements in biology.

The outstanding scientists here cannot be done with money, and although it has the name of non-governmental research, it will never go so smoothly without the strong support of the government. In this tide of technology, what Meng Qian can do is to participate, hold more shares, and share the future.

Meng Qian walked around the various departments of the artificial intelligence company for several days.

In addition to the AI Lab, which is a world-renowned institution, the company actually has a commercial department, such as the intelligent mainframe launched in cooperation with IBM, which is aimed at enterprise users and is specially provided to demanding departments such as large company servers, banks or securities institutions.

The commercialization of primary AI has already begun, and in addition to enterprise users, the company has many concept divisions, such as mobile intelligence for consumer users, and its application is bound to set off a new trend; The Intelligence & Robotics division, combined with intelligent machines, is very future-promising.

Meng Qian walked around and was also inspired a lot.

He had considered customizing an AI butler for himself before, and now there are ready-made ones that can be used. Based on the existing platform, he was able to transform a housekeeper that better met his own requirements, and even after simplification, it could also be promoted to ordinary consumer users.

Think about it, what kind of prospects would it be if Windows was smart?

No matter how bold the new three-dimensional system is coupled with intelligence, will Microsoft's system still have a way to live?

The company's solid foundation and large research team enabled him to realize many of his business plans and visions.

There is a premise for all this - he needs to hold shares.

He can't just bring technology and not enjoy its benefits, he has to invest more money, borrow the perfect resources here, and develop better projects.

……

The deal of this new drug has become the focus of Meng Qian's money-swapping plan.

Pfizer and Eli Lilly are the two most direct competitors, and the other giants, although they have not yet moved, are also secretly watching closely, evaluating the technology, analyzing its effects and prospects, and once there are enough attractive benefits, more people will take action.

At this moment, another heroic man appeared.

Onyx Pharmaceuticals announced a partnership with Montessori Pharmaceuticals and is willing to help with clinical issues with new drugs.

Although the news is brief, one of the participants is a powerful giant.

Regardless of why they are intervening, both Pfizer and Eli Lilly are feeling the pressure. Previously, the main reason for their bidding was that there was no phase III clinical data, whether they could pass the trial, and whether they could pass the review of the food and drug administration. And now that Onix is meddling, is there still a problem?

Phase 3 clinical trial? Onix has its own channels and funds, and it can be launched immediately.

Food and Drug Administration Audit? Behind the huge capital, how can there be no inextricable connection with the government?

Onyx is a spoiler who does not play cards according to common sense, they are not only willing to cooperate with the clinic, but also willing to buy out this technology at a higher price - in the eyes of the other two opponents, there are many meanings, it may be a deliberate act of coaxing, but it may also be real power.

The CEOs of Pfizer and Eli Lilly are inclined to the latter when they think of the effects of the new drug.

The new drug is definitely powerful, combining anti-ED and time delay, and it has departed from the level of traditional ED drugs.

It is leather. Lifetime upgrade product!

The upgrade means that its market will be larger, originally only ED patients like to use, but now the time-delayed crime function will attract more people, including normal people, to try! Driven by technology, the market will definitely double and bring more benefits!

So in the negotiation with Pfizer, the people on Meng Qian's side made an offer: "If the gentlemen think that the phase III clinical trial will take more risks, my client can reduce the cash for the upfront transaction." ”

Pfizer's representatives all wanted to reduce the excessive cash investment, but they also knew that the other party was an old fox or a professional: "What about the sharing aspect? ”

"We're willing to reduce the cash transaction volume to $2.5 billion, and the corresponding patent licensing will charge 5.2 percent of sales, or 18 percent of the net profit of the product."

The people on Pfizer's side are lost in thought.

They're doing a quick math that whether it's 5.2% of sales or 18% of net profit, the amount of money required is similar. However, from the perspective of professional accounting, sales can be less profitable, but they cannot cover up sales, and the latter, which seems to be more costly, is actually more suitable.

5.2%No one thinks it's small, this guy is a vampire!

While the Pfizer representative was thinking, Johnson, who was in charge of the negotiations, looked at his watch: "Gentlemen, you can think about it first, we have other arrangements later." ”

The Pfizer folks do need to consider that this is a bit of a big price to pay – but from a risk aversion perspective, the less money you have to make an upfront deal, the better.

If they pay 6 billion yuan to buy out this technology at one time, they will worry about whether the new drug can perform well in the phase III clinical trial and whether the FDA can pass the review with confidence.

When they left, they just went out and met a senior Eli Lilly executive who came to negotiate.

When competitors meet, they want to kill each other, but for the sake of grace, both sides pretend not to see each other, and pass by silently.

But this scene stimulated Pfizer!

Ian Reed no longer wants to tolerate the feeling of missing an opportunity, they want to maintain the face of the pharma boss, they have to outperform their opponents!

So his old man actually flew over in person to talk about cooperation face-to-face.

In the end, whether the boss is domineering, or the company has money, this cooperation quickly made Meng Qian nod.

Pfizer's conditions are: $2.2 billion in cash and short-term realizable assets, plus a 20% share of sales profits during the patent period.

The total expected by Meng Qian is $2.2 billion plus $5 billion in future gains, which is more than the highest estimate of $7 billion.

Pfizer's handwriting also quickly spread around the world.

Pfizer, the pharmaceutical giant, actually has a day when it bows its head and admits to buying technology!

And the company that sells actually has to eat 20% of the profit dividend! This is simply a clear attempt to pit Pfizer, but for the sake of hegemony, interests and stock prices, Pfizer can only smash its teeth and swallow it in its stomach - it doesn't matter if cooperation is made fun of, they control the future.

The volatility of the stock market can justify their strategy.

The outside world makes fun of them does not mean that investors are blind, and after the news of the cooperation came out, Pfizer's stock has been rising all the way.

Pfizer, whose market capitalization once fell below the $200 billion mark, has finally risen again.

Behind the seemingly depressed expression of Ian Reed, he has already been happy, according to confidential new drug data, it will usher in a new era.

Also happy is Meng Qian.

The $2.2 billion in cash will arrive soon, and he has $2.05 billion in addition to the $150 million in compensation.

Of this money, he plans to invest $1.5 billion in artificial intelligence companies, holding 5% of the shares, and the remaining 550 million yuan will be partially invested in the Montson Group, which will be used for new drug clinics, stem cell engineering, etc. - this money can last for two years, and he will not be short of money after two years.

Many of his industries are short of money in the near future, and after a virtuous cycle, funds will come in a surge.

The share of ED drugs alone is expected to bring him more than 300 million yuan in revenue every year in the future.

At the same time, it can also make the company famous, because the cooperation with Pfizer and Onix has attracted people's attention to the Montessori pharmaceutical - they are not stupid, and immediately take the opportunity to spread advertisements, such as promoting women's cold medicine, which is no less technical and effective than men's ED, as well as new drugs that can grow taller and stronger.

If it had been before, probably no one would have believed the.

But Pfizer's willingness to risk a big deal to cooperate with them is a testament to its strength.

Pfizer is so expert stupid?

Not stupid, they're cunning! It further emphasizes the technical ingenuity of Montessori Pharmaceutical.

There was even news that Eli Lilly, who had failed in the negotiations, was not discouraged, and they still wanted to compromise women. Cold drugs to cooperate.

Regardless of whether the deal will be closed or not, Montson has successfully taken the first step.

====

PS: It's noon on the two shifts